|Bid||60.05 x 200|
|Ask||62.10 x 100|
|Day's range||66.20 - 69.05|
|52-week range||28.35 - 136.90|
|PE ratio (TTM)||N/A|
|Earnings date||1 Mar 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||98.56|
Puma Biotechnology, Inc. , a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Thursday, March 1, 2018 following release of its fourth quarter and full year 2017 financial results.
Puma Biotechnology, Inc. , a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 3:30 p.m.
Puma (PBYI) enters an exclusive agreement with CANbridge under which the latter will seek regulatory approval for Nerlynx in China and develop and commercialize it in the region.
Puma Biotechnology, Inc. , a biopharmaceutical company, and CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, have entered into an exclusive agreement under which CANbridge will develop and commercialize NERLYNX® in mainland China, Taiwan, Hong Kong, and Macau .
Puma Biotechnology, Inc. , a biopharmaceutical company, announced that initial results from the company’s ongoing SUMMIT Phase II ‘basket’ clinical trial of PB272 in patients with tumors harboring HER2 or HER3 mutations were published in the journal Nature.
Puma's licensing agreement for breast cancer drug Nerlynx won't inhibit takeover interest for Puma, an analyst said Tuesday.
Investors need to pay close attention to Puma Biotechnology (PBYI) stock based on the movements in the options market lately.
Puma Biotechnology, Inc. , a biopharmaceutical company, and Medison Pharma Ltd, Israel's leading commercial partner for innovative pharmaceuticals, have entered into an exclusive agreement under which Medison will commercialize NERLYNX® in Israel.
Puma Biotechnology, Inc. , a biopharmaceutical company, today announced that on January 16, 2018 the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement stock option to purchase 90,000 shares of Puma common stock to Douglas Hunt in connection with Mr.
Puma's (PBYI) shares decline after CHMP conveyed the company that the former will probably vote against the approval of breast cancer drug Nerlynx at the CHMP meeting scheduled in February.
Puma Biotechnology’s shares are getting pounded today after its breast cancer drug neratinib suffered a regulatory setback that makes a 2018 European launch unlikely. One analyst says the news “makes the M&A narrative more challenging.”
Puma Biotechnology Inc. shares dropped 26.7% in premarket trade on Wednesday after the company said a European Medicines Agency committee completed a negative vote for its breast cancer therapy neratinib, ...
Puma Biotechnology Inc. shares fell Tuesday after the biotech company said it will likely not get a positive result on its European marketing application for a breast cancer treatment. Puma Biotechnology ...
Puma Biotechnology, Inc. announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has communicated a negative trend vote after meeting with the Company today to discuss the Marketing Authorisation Application for neratinib for the extended adjuvant treatment of early stage HER2-positive breast cancer.
Puma's (PBYI) shares jump in a year's time on its cancer drug Nerlynx's approval in the United States coupled with strategic collaborations.
Puma, Clovis and Incyte could outperform other midcap biotechs this year, an analyst says, listing the trio as his favorites for 2018.
Puma Biotechnology, Inc. , a biopharmaceutical company, has been selected for addition to the NASDAQ Biotechnology Index as part of the NBI’s annual re-ranking of biotechnology and pharmaceutical companies listed on The NASDAQ Stock Market® that meet NBI’s eligibility criteria.
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that the European Medicines Agency (EMA) has requested that the Scientific Advisory Group on Oncology provide an opinion on the clinical aspects of the Marketing Authorization Application (MAA) for neratinib at a meeting to be held on January 11, 2018. In Europe, neratinib is an investigational therapy for the extended adjuvant treatment of early stage HER2-positive breast cancer that has previously been treated with a trastuzumab containing regimen. The Scientific Advisory Group on Oncology is convened at the request of the EMA to provide independent recommendations on scientific or technical matters related to pediatric and adult clinical oncology and hematology, or on any other scientific issue relevant to the work of the EMA that relates to this area.
Puma Biotechnology, Inc. , a biopharmaceutical company, announced that the European Medicines Agency has requested that the Scientific Advisory Group on Oncology provide an opinion on the clinical aspects of the Marketing Authorization Application for neratinib at a meeting to be held on January 11, 2018.
Daiichi Sankyo Company, Limited and Puma Biotechnology, Inc. have announced a preclinical research collaboration with Memorial Sloan Kettering Cancer Center to explore the combination of Daiichi Sankyo’s investigational antibody drug conjugate DS-8201 and Puma Biotechnology’s irreversible pan-HER tyrosine kinase inhibitor neratinib in HER2-mutated or HER2-positive solid tumors.